Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(15)
•••
Comment by PinnacleXon Sep 06, 2019 7:24pm
100 Views
Post# 30104183

RE:RE:RE:RE:RE:RE:RE:Weekly Sales Update

RE:RE:RE:RE:RE:RE:RE:Weekly Sales Update
CreatingApe wrote: Mmmm very nice Mr. Pinnacle, very nice indeed.  I did not know the Ignore button existed, that is the most useful thing you have ever posted on this message board!! Bravo. I will gladly hit the "mute" button and be done suffering your daily rants. Thank you.

And I will go back to traveling around the world by motorbike like I have been doing for the past 7 years... and I just turned 30. Not sure what basement you are referring to as it seems you are the troll here :)  Life is what you make it Mr. Pin-head.


This past year has been tough for us here, but I am still proud to be invested in this company. The future is bright and many things are in motion. Patience is needed, this is long term investing after all.

Have a good weekend everyone.  And an enthusiastic goodbye to you Pinnacle.




Hopefull,y that imaginary motorcylce of yours breaks down and you never come back, its not like you ever contributed to this board anyways.  

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities